Product image of Meglithan (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Meglithan

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Meglithan (Metformin Hydrochloride, Linagliptin)

Metformin Hydrochloride and Linagliptin, the active ingredient in Meglithan, is a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving insulin sensitivity and enhancing glucose‑dependent insulin secretion. It is indicated for patients who require combined therapy to achieve glycemic targets.

GNH India supplies Meglithan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Manufacturer / TM Owner

Pharmapath Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meglithan is used in the management of type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents.

  • Type 2 diabetes mellitus (monotherapy): improves glycemic control when used with diet and exercise.
  • Type 2 diabetes mellitus (combination therapy): provides additional HbA1c reduction when added to other oral antidiabetic drugs or insulin.
  • Adjunct to lifestyle modification: helps achieve target fasting glucose levels when combined with diet and exercise.

How It Works

  • Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, while linagliptin inhibits the enzyme dipeptidyl peptidase‑4, leading to higher endogenous incretin levels that stimulate glucose‑dependent insulin secretion and suppress glucagon release, together producing a complementary reduction in blood glucose.

Side Effects

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Headache: mild to moderate intensity.
  • Upper respiratory tract infection: nasopharyngitis or sore throat.
  • Metallic taste: transient alteration in taste perception.
  • Fatigue: general feeling of tiredness.
  • Mild hypoglycemia: especially when combined with insulin or sulfonylureas.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic complication.
  • Severe hypoglycemia: marked low blood glucose requiring assistance.
  • Pancreatitis: acute inflammation of the pancreas.
  • Anaphylactic reaction: severe allergic response with rash, swelling, or difficulty breathing.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.
  • Renal impairment worsening: decline in kidney function associated with metformin accumulation.

Precautions & Warnings

Before initiating therapy, evaluate patient-specific factors and monitor regularly.

  • Renal function: assess eGFR and avoid use in severe renal impairment.
  • Hepatic impairment: use with caution and monitor liver enzymes.
  • Risk of lactic acidosis: discontinue metformin if patient develops conditions predisposing to hypoxia.
  • Pregnancy and lactation: safety not established; weigh potential benefits against risks.
  • Drug interactions: review concomitant medications for agents that may affect glucose control or renal clearance.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Meglithan may interact with several medicines that affect glucose metabolism or renal clearance.

Major Interactions (Avoid)

  • Iodinated contrast agents in patients with reduced renal function: may precipitate acute kidney injury.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase linagliptin exposure.
  • Insulin or sulfonylureas: may cause severe hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Cimetidine: may modestly raise linagliptin plasma levels.
  • Diuretics (e.g., furosemide): can affect metformin elimination.
  • Alcohol consumption: increases risk of lactic acidosis, especially with metformin.

Frequently Asked Questions

Meglithan is prescribed for the treatment of type 2 diabetes mellitus. It helps lower blood glucose levels by combining the actions of metformin, which improves insulin sensitivity, with linagliptin, which enhances insulin secretion in response to meals.

Metformin Hydrochloride decreases hepatic glucose production and increases peripheral uptake of glucose, thereby improving insulin sensitivity. This reduces fasting plasma glucose and contributes to overall glycaemic control.

The dosage of Meglithan is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule.

The safety of Meglithan in pregnancy and lactation has not been established. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing women.

To request Meglithan, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meglithan combines a biguanide (metformin) and a DPP‑4 inhibitor (linagliptin) in a single tablet, offering complementary mechanisms that can achieve greater HbA1c reduction than either component alone. Compared with sulfonylureas, it carries a lower risk of hypoglycemia, and unlike some other combinations, it does not require dose titration for the linagliptin component.

Meglithan tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Meglithan is taken orally, usually once daily with or after a meal. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and severe hypoglycemia, especially when used with insulin or sulfonylureas. Pancreatitis and allergic reactions such as anaphylaxis are also rare but serious concerns.

Meglithan is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or linagliptin, and in individuals with a history of lactic acidosis. It should also be avoided in patients with acute or chronic metabolic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT